weekly_roundup
BioTechSign Daily Catalyst Roundup - November 21, 2026
Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 21, 2026
Daily Biotech Catalyst Digest: November 21, 2026
EYPT leads the current BioTechSign screen at 83.5/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| EYPT | EyePoint, Inc. | 83.5 | A | clinical activity 100%, short interest 50%, dilution risk 47% |
| MLTX | MoonLake Immunotherapeutics | 80.5 | A | clinical activity 100%, short interest 50%, publication signal 35% |
| GRFS | Grifols SA | 74.8 | B | publication signal 100%, clinical activity 100%, dilution risk 19% |
| ARGX | argenx SE | 74.0 | B | publication signal 100%, clinical activity 100%, dilution risk 15% |
| NUVB | Nuvation Bio | 73.6 | B | clinical activity 88%, PDUFA timing 75%, short interest 70% |
| BBIO | BridgeBio Pharma | 73.2 | B | PDUFA timing 100%, publication signal 100%, clinical activity 100% |
Recent Grade-Change Queue
- SMMT (Summit Therapeutics Inc.) currently grades F with a 19.6/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 25%.
- INSM (Insmed Incorporated) currently grades D with a 38.8/100 catalyst score. Main inputs: publication signal 100%, clinical activity 58%, dilution risk 50%.
- TENX (Tenax Therapeutics, Inc.) currently grades B with a 70.8/100 catalyst score. Main inputs: short interest 90%, clinical activity 75%, dilution risk 53%.
- SLS (SELLAS Life Sciences Group, Inc.) currently grades F with a 28.0/100 catalyst score. Main inputs: short interest 90%, clinical activity 42%, publication signal 20%.
- ORIC (Oric Pharmaceuticals, Inc.) currently grades D with a 46.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 50%, short interest 50%.
- FDMT (4D Molecular Therapeutics, Inc.) currently grades C with a 52.4/100 catalyst score. Main inputs: publication signal 90%, short interest 70%, clinical activity 54%.
- NKTR (Nektar Therapeutics) currently grades C with a 52.7/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 75%.
- MLYS (Mineralys Therapeutics, Inc.) currently grades C with a 53.6/100 catalyst score. Main inputs: PDUFA timing 75%, dilution risk 51%, short interest 50%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.